- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07619820
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
A Phase 1b, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease Undergoing Dialysis
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Trial Registration Coordinator
- Telefoonnummer: +16108784697
- E-mail: clinicaltrials@cslbehring.com
Studie Locaties
-
-
-
Beijing, China, 100044
- Werving
- Peking University People's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Participants has provided written informed consent and is willing and able to adhere to all protocol requirements.
- Aged 18 or older, inclusive, at the time of providing written informed consent.
- Diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks before Screening.
Exclusion Criteria:
- Exclusion related to risk of infection: concomitant use of systemic immunosuppressant agents, primary immunodeficiency, positive test for active tuberculosis (TB), history of latent TB without completion of full course of prophylactic treatment, evidence of human immunodeficiency virus infection during Screening, seropositivity for hepatitis B surface antigen or positive hepatitis B virus (HBV) DNA during Screening, seropositivity for hepatitis C virus ribonucleic acid during Screening, diagnosis of clinically significant active infection, history of / OR current invasive fungal infection OR other opportunistic infection OR recurrent cellulitis (defined as 2 or more episodes in the year prior to screening), administration of a live vaccine within 6 weeks of start of Screening, presence of urinary catheter, or evidence of wet gangrene or nonhealing ulcers.
- Exclusion related to laboratory abnormalities: abnormal liver function tests, neutropenia, thrombocytopenia, or significant anemia.
- Exclusion related to medical history: any life-threatening disease expected to result in death within 12 months (other than cardiovascular disease), evidence of active hepatic disease and / or moderate or severe hepatic impairment, recent unplanned hospitalization (< 30 days) prior to Screening, recent (< 3 months) major surgery or planned major surgery known at the time of Screening, poorly controlled hypertension, a present or previous (< 5 years) malignancy except for basal cell carcinoma, fully excised squamous cell carcinoma of the skin, or nonrecurrent (< 5 years of Screening) cervical carcinoma in situ, active or recent (< 30 days of Screening) clinically severe bleeding, a scheduled kidney transplant within 6 months of Screening, a history of anaphylaxis or hypersensitivity to CSL300 or any constituents of the product, or a history of demyelinating disorders.
- Exclusion related to risk of gastrointestinal perforation: a history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease (< 12 months before Screening), a history of diverticular disease or diverticulitis (except if disease has been fully excised). An incidental finding of diverticulosis (presence of small diverticula) and no history of symptoms, complications, or any episodes requiring treatment may be eligible for the study based on investigator's judgment. However, any history of complications, inflammation, or infection suggestive of diverticulitis or diverticular disease is exclusionary, inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis except if fully excised, or prior gastric bypass surgery.
- Exclusion related to treatment compliance: evidence of inadequate dialysis, unwillingness or inability to comply with study procedures, a history of noncompliance with medical treatments, or ongoing alcohol or illicit substance abuse.
- Current or recent participation in research study involving an experimental agent < 3 months of Screening.
- Pregnant, breastfeeding, or unwillingness to practice adequate contraception during the study and for 5 months after the last dose of investigational product.
- The presence of any condition that in the opinion of the Investigator would (1) compromise the safety of the participant in case of participation in the study, (2) compromise the quality of the data, and / or (3) limit the life expectancy of the participant to < 1 year.
- The Sponsor determines that the participant is no longer needed for participation in study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: CSL300 (Clazakizumab)
Participants will receive CSL300 once every 4 weeks (Q4W) as a slow intravenous (IV) bolus, for a total of 20 weeks during the Treatment Period.
|
CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).
|
|
Placebo-vergelijker: Placebo
Participants will receive a placebo matching to CSL300 Q4W as a slow IV bolus, for a total of 20 weeks during the treatment period.
|
Placebo is a solution for injection matching the excipient content and concentration of the CSL300 product, minus the active ingredient.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Area Under the Concentration-time (AUC) Curve of CSL300 Over 1 Dosing Interval After Multiple Doses (AUC0-tau,MD)
Tijdsspanne: Day 85 up to Day 113
|
Day 85 up to Day 113
|
|
Trough Concentration at Steady State (Ctrough,ss)
Tijdsspanne: Up to Day 141
|
Up to Day 141
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interests (AESIs)
Tijdsspanne: Up to Day 225 (End of Study [EoS])
|
The following adverse events (AEs) are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.
|
Up to Day 225 (End of Study [EoS])
|
|
Percentage of Participants With TEAEs, SAEs, and AESIs
Tijdsspanne: Up to Day 225 (EoS)
|
The following AEs are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.
|
Up to Day 225 (EoS)
|
|
Percentage of Participants With a Clinically Significant Change From Baseline in Laboratory Test Results
Tijdsspanne: At Baseline and up to Day 225 (EoS)
|
Laboratory assessments will include hematology parameters such as white blood cells (leukocytes), neutrophils, and platelets; chemistry evaluations including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin; a lipid panel comprising total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; and immunogenicity testing.
|
At Baseline and up to Day 225 (EoS)
|
|
Number of Participants With Antidrug Antibodies
Tijdsspanne: At Days 1, 29, 85, and 169
|
The detection of antibodies to CSL300 will be performed using a validated immunoassay method.
|
At Days 1, 29, 85, and 169
|
|
Maximum Observed Concentration (Cmax) of CSL300
Tijdsspanne: Up to Day 169
|
Up to Day 169
|
|
|
Area Under the Concentration-Time Curve From Time 0 to Day 28 (AUC0-28d) of CSL300
Tijdsspanne: Up to Day 28
|
Up to Day 28
|
|
|
Trough Concentration (Ctrough) of CSL300
Tijdsspanne: Up to Day 141
|
Up to Day 141
|
|
|
Time to Reach Cmax (Tmax) of CSL300
Tijdsspanne: Up to Day 85
|
Up to Day 85
|
|
|
Change From Baseline on log-scale High-Sensitivity C-reactive Protein (hs-CRP)
Tijdsspanne: At Baseline, Week 12, and Week 24
|
At Baseline, Week 12, and Week 24
|
|
|
Plasma Interleukin-6 (IL-6) Free and Total Levels
Tijdsspanne: At Weeks 12 and 24
|
At Weeks 12 and 24
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Endocriene systeemziekten
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Chronische ziekte
- Ziekte attributen
- Metabole ziekten
- Glucosemetabolismestoornissen
- Nierinsufficiëntie
- Arteriosclerose
- Arteriële occlusieve ziekten
- Nierinsufficiëntie, chronisch
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Suikerziekte
- Nierfalen, chronisch
- Atherosclerose
Andere studie-ID-nummers
- CSL300_1001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
Proposed research should seek to answer a previously unanswered important medical or scientific question.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .